Zoetis ZTS
Quarterly report 2024-Q3
added 11-04-2024
Country |
USA |
IPO year |
2013 |
Industry |
Biotechnology |
Stock Exchange |
NYSESPB |
CEO |
Mr. Juan Alaix |
Employees in the company |
10 600 |
Shares |
461 M |
Market Cap[1] |
$ 80.6 B |
EBITDA (LTM) |
$ 498 M |
P/E (LTM) |
- |
P/S (LTM) |
- |
EPS (LTM) |
- |
Zoetis is a global leader in animal health and veterinary medicine, providing a wide range of products and services to improve animal health, including medicines, vaccines, diagnostic tests, and animal health management programs. The company was created in 2013 after being spun off from Pfizer Inc., and is headquartered in New Jersey, USA.
Zoetis works with farmers, veterinarians, and other professionals in the livestock and animal health industries around the world. The company is committed to innovation and developing new products and services to improve animal health and provide more effective animal health management. Zoetis is also actively involved in social responsibility, supporting various charitable organizations and programs.
Today, Zoetis has a presence in over 100 countries and serves millions of animals. The company is constantly striving to improve its products and services to meet the needs of its customers and partners.
Other stocks of industry "Biotechnology"
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.